Ignite Creation Date:
2024-05-06 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 2:29 PM
Study NCT ID:
NCT05315882
Status:
COMPLETED
Last Update Posted:
2022-04-07
First Post:
2022-03-08
Brief Title:
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis GVHD PROPHYLAXIS ERA
Sponsor:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Organization:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Study Overview
Official Title:
Cytomegalovirus Infection Indirect Effects and Mortality in Hematopoietic Stem Cell Transplantation With Cyclophosphamide Post-transplant
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CY-CMV-2020
Brief Summary:
Multicentre observational retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients haplo vs no haplo HSCT with intervention both postransplant cyclophosphamide as GvHD prophylaxis using a database with information from historical clinic data
Detailed Description:
The overall aim of the study is to to analize CMVi after PTCy for GVHD prophylaxis with a detailed description of CMVi and recurrences direct and indirect consequences in a HSCT population comparing two cohorts haploidentical HSCT vs no haploidentical HSCT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None